- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
THC and CBD may reduce tics and psychiatric comorbidity associated with severe Tourette syndrome
In a study published in NEJM Evidence, researchers found that oral 1:1 THC: CBD (9-tetrahydrocannabinol: cannabidiol) formulation titrated upward over six weeks up to a daily dose of 20 mg of THC and 20 mg of CBD led reduces tics as measured by the total tic score on the Yale Global Tic Severity Scale or YGTSS. It also reduces obsessive-compulsive symptoms and anxiety without major adverse effects.
Speaking about the strengths of the research, Mosley et al. and colleagues said that tic reduction was observed in both interviewer-led and video-based assessments of tic severity.
The characteristic of Tourette syndrome is chronic motor and vocal tics. Based on previous evidence, it is known the benefits of cannabis products containing THC and the coadministration of CBD improve the side-effect profile and safety.
In the present study, severe Tourette syndrome patients were randomly assigned to a 6-week treatment period with escalating doses of an oral oil. This contained THC and CBC, both at 5 mg/ml. This was followed by a 6-week course of a placebo, or vice versa, separated by a 4-week washout period.
The primary outcome was the total tic score on YGTSS. The range is from 0 to 50; the higher the score, the more the severity of the symptoms.
Video-based assessment of tics, global impairment, anxiety, depression, and obsessive-compulsive symptoms were the secondary outcomes measured by them.
The key results of the study are:
- Researchers enrolled 22 participants.
- In the active and placebo group, the reduction in total tic scores was 8.9 and 2.5, respectively.
- In active treatment, there was a more significant decrease in tics.
- Researchers reported a correlation between plasma 11-carboxy-tetrahydrocannabinol levels and the primary outcome. This was attenuated after the exclusion of an outlier.
- In the placebo group, the common adverse effect was headache.
- The cognitive difficulties, slowed mentation, memory lapses, and poor concentration were the reported adverse effects in the active group.
They said treating severe Tourette syndrome with THC and CBD reduced tics. This treatment also reduces impairment due to tics, anxiety, and obsessive-compulsive disorder.
As acknowledged, Wesley Medical Research Institute, Brisbane, and the Lambert Initiative for Cannabinoid Therapeutics funded the study.
Further reading:
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751